Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 12 of 5804
-
New eye drug aims to restore vision in Diabetes-Related swelling
Disease control Not yet recruitingResearchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Brain cancer vaccine targets survivin protein to boost immune attack
Disease control Not yet recruitingThe overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.
Phase: PHASE2 • Sponsor: Beijing Tricision Biotherapeutics Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy may treat skin cancer in kidney transplant patients without rejection
Disease control Not yet recruitingThis is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemipli…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Blood test could signal when to switch breast cancer therapy before tumors grow
Disease control Not yet recruitingRationale: In patients with metastatic breast cancer, fragments of tumor DNA called "circulating tumor DNA" or "ctDNA" can be detected in the blood. When the level of ctDNA increases, it often means that treatment is no longer effective and that the disease is likely to progress…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in ovarian cancer
Disease control Not yet recruitingThis study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThe objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization…
Phase: PHASE1, PHASE2 • Sponsor: Servier • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for myeloma patients: could ramantamig plus daratumumab outperform standard care?
Disease control Not yet recruitingThe main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative compl…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under mainten…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug aims to keep schizophrenia in check
Disease control Not yet recruitingThe purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
A daily pill for obesity? zenagamtide faces its biggest test yet.
Disease control Not yet recruitingThe purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being teste…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered immune cells take on deadly childhood brain cancer
Disease control Not yet recruitingThis study is being conducted in patients with GPC3-positive brain tumors that have recurred or have not responded to standard therapy. Atypical teratoid rhabdoid tumors (ATRT) are aggressive tumors with poor outcomes and limited treatment options, particularly in young children.…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
A made-to-order DNA vaccine takes aim at liver cancer's return
⭐️ VACCINE ⭐️ Not yet recruitingThis is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to underg…
Phase: PHASE2 • Sponsor: Geneos Therapeutics • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 25, 2026 00:00 UTC
-
New hope for sickle cell: Half-Matched transplants aim to cut complications
Disease control Recruiting nowThe purpose of this study it to evaluate a reduced toxicity conditioning regimen for haploidentical donor HCT followed by a GVHD prophylaxis regimen comprising of post-transplant cyclophosphamide, sirolimus and abatacept with the goal to improve the GVHD-free rejection-free survi…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingA Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
One-Time gene injection aims to rescue sight in rare childhood blindness
Disease control Not yet recruitingThis study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a …
Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New antibody drug aims to outsmart Treatment-Resistant myeloma
Disease control Not yet recruitingThe goal of this Phase 2 clinical trial is to learn whether YKST02 is effective and safe in adults with relapsed or refractory multiple myeloma. The study will also evaluate how YKST02 is processed by the body (pharmacokinetics), how it affects the body (pharmacodynamics), and wh…
Phase: PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Light-Activated therapy targets pancreatic tumors during surgery
Disease control Not yet recruitingThis is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
Phase: PHASE1, PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingPancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates. Many PDACs arise from non-invasive precursor lesions that develop over years, including pancreatic in…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
Blood filter could shield vessels in septic shock
Disease control Not yet recruitingThis study aims to investigate the effects of adjunctive CytoSorb hemoadsorption therapy versus standard medical treatment on endothelial dysfunction in patients with refractory septic shock. The investigators hypothesize that hemoadsorption mitigates endothelial and glycocalyx i…
Phase: NA • Sponsor: Semmelweis University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a simple oxygen mask boost stroke recovery hours after symptoms start?
Disease control Not yet recruitingAlthough endovascular therapy (EVT) has substantially improved recanalization rates and extended the treatment window for acute ischemic stroke, fewer than half of patients achieve functional independence despite successful reperfusion. Growth of the ischemic core before reperfus…
Phase: PHASE3 • Sponsor: Weifang Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC